Loading clinical trials...
Loading clinical trials...
An Open-Label, Singe Arm, Multicenter Study to Investigate the Safety and Efficacy of Atezolizumab (Tecentriq) in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions
Interventions
Atezolizumab
Locations
7
China
Peking Union Medical College Hospital
Beijing, China
Sichuan Cancer Hospital
Chengdu, China
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department
Hangzhou, China
Harbin Medical University Tumor Hospital; Department of Surgery; Pharmacy
Harbin, China
Taizhou Hospital of Zhejiang Province
Linhai, China
Fudan University Shanghai Cancer Center; Medical Oncology
Shanghai, China
Start Date
July 3, 2019
Primary Completion Date
August 11, 2022
Completion Date
August 11, 2022
Last Updated
September 9, 2022
NCT07190248
NCT06305754
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions